Matt Hewitt
Stock Analyst at Craig-Hallum
(1.68)
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
SLP Simulations Plus | Maintains: Buy | 45 36 | 13.87 | 159.55% | 8 | Jun 13, 2025 | |
CSBR Champions Oncology | Maintains: Strong Buy | 8 12 | 6.28 | 91.08% | 4 | Mar 12, 2025 | |
BLFS BioLife Solns | Maintains: Strong Buy | 30 32 | 22.43 | 42.67% | 4 | Nov 13, 2024 | |
OMCL Omnicell | Maintains: Strong Buy | 45 64 | 30.85 | 107.46% | 5 | Oct 31, 2024 | |
LGND Ligand Pharmaceutica... | Maintains: Strong Buy | 135 140 | 147.14 | -4.85% | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 25 10 | 1.88 | 431.91% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 35 30 | 18.61 | 61.2% | 3 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 2 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 23 | 10.05 | 128.86% | 1 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 22 16 | 12.49 | 28.1% | 4 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 7 | 1.31 | 434.35% | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 207 200 | 111.93 | 78.68% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 10 | 1.97 | 407.61% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Hold | 5 2 | n/a | n/a | 2 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 3 2 | n/a | n/a | 1 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Hold | 67 30 | 6.78 | 342.48% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 400 | 1.12 | 35614.29% | 1 | Jan 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 21 30 | 79.13 | -62.09% | 3 | Jul 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 11 | 10 | 10% | 1 | Jul 24, 2017 |